

THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND TNF INHIBITORS IN BIO-NAÏVE PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

Triana Lobaton

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

In bio-naïve IBD patients, vedolizumab and anti-TNF agents showed similar overall efficacy at one year, though anti-TNF demonstrated faster biochemical response after induction.

KEY POINTS

- This retrospective Belgian study compared vedolizumab (42 patients) to anti-TNF therapy (57 patients) in bio-naïve IBD patients treated from January 2018 to June 2021.
- After induction, anti-TNF achieved significantly higher biochemical response and remission rates compared to vedolizumab (87.8% vs. 67.6%, $P=0.026$), with the difference persisting after adjustment for confounders (aOR 3.83, $P=0.049$).
- At one year, no significant differences were observed between groups for clinical, biochemical, or endoscopic response and remission rates.
- Treatment survival showed no significant difference between anti-TNF and vedolizumab (aHR 0.947, $P=0.913$) after adjustment for propensity scores and concomitant medication use.
- The study concluded that both therapies had similar efficacy in bio-naïve IBD patients, with anti-TNF showing an advantage in onset of action.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/782bc2f8-743c-11ee-b6e4-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.